Renal Cell Carcinoma

FDA Approves Combo Tx for Intermediate, Poor-Risk Advanced Kidney Cancer

By April 16, 2018

The approvals for nivolumab and ipilimumab were based on CheckMate 214, a randomized open-label trial.

Cabometyx Approved as First-Line Tx for Advanced Renal Cell Carcinoma

By December 20, 2017

Approval provides for treatment in the first-line setting.

Sutent Approved for Patients at High Risk of Recurrent RCC

By November 17, 2017

Sutent was first approved in 2006 for the treatment of certain patients with gastrointestinal stromal tumors and advanced renal cell carcinoma.